Patents by Inventor Andrew Zeitlin

Andrew Zeitlin has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20210032596
    Abstract: Provided herein are methods of producing erythrocytes from hematopoietic cells, particularly hematopoietic cells from placental perfusate in combination with hematopoietic cells from umbilical cord blood, wherein the method results in accelerated expansion and differentiation of the hematopoietic cells to more efficiently produce administrable erythrocytes. Further provided herein is a bioreactor in which hematopoietic cell expansion and differentiation takes place.
    Type: Application
    Filed: March 12, 2020
    Publication date: February 4, 2021
    Applicant: Celularity, Inc.
    Inventors: Mohammad A. Heidaran, Xiaokui Zhang, Lin Kang, Andrew Zeitlin, Vanessa Voskinarian-Berse, Stewart Abbot
  • Publication number: 20190330592
    Abstract: Provided herein are methods of producing natural killer cells using a two-step expansion and differentiation method. Also provided herein are methods of suppressing tumor cell proliferation, of treating individuals having cancer or a viral infection, comprising administering the NK cells produced by the method to an individual having the cancer or viral infection.
    Type: Application
    Filed: July 3, 2019
    Publication date: October 31, 2019
    Applicant: Celularity, Inc.
    Inventors: Robert J. HARIRI, Mohammad A. HEIDARAN, Stephen JASKO, Lin KANG, Eric LAW, Ajai PAL, Bhavani STOUT, Vanessa VOSKINARIAN-BERSE, Andrew ZEITLIN, Xiaokui ZHANG
  • Publication number: 20190263894
    Abstract: Antibody variants originating from the monoclonal antibody 13C6, and wherein the N-glycosylation site within the constant region of the heavy chain contains a glycan that is either wild-type or largely devoid of fucose residues, will bind Ebola virus glycoprotein and provide surprising efficacy in treating animals or humans infected with Ebola virus when used in combination with one or more additional anti-Ebola mAbs. Such antibody cocktails are vastly superior to other known monoclonal antibodies or monoclonal antibody combinations in treating animals and humans infected with the Ebola virus.
    Type: Application
    Filed: April 19, 2019
    Publication date: August 29, 2019
    Inventors: Andrew Hiatt, Larry Zeitlin, Kevin Whaley, Michael Pauly
  • Publication number: 20190247501
    Abstract: Antibody variants originating from the monoclonal antibody 13C6, and wherein the N-glycosylation site within the constant region of the heavy chain contains a glycan that is either wild-type or largely devoid of fucose residues, will bind Ebola virus glycoprotein and provide surprising efficacy in treating animals or humans infected with Ebola virus when used in combination with one or more additional anti-Ebola mAbs. Such antibody cocktails are vastly superior to other known monoclonal antibodies or monoclonal antibody combinations in treating animals and humans infected with the Ebola virus.
    Type: Application
    Filed: March 29, 2019
    Publication date: August 15, 2019
    Inventors: Andrew Hiatt, Larry Zeitlin, Kevin Whaley, Michael Pauly
  • Publication number: 20170240860
    Abstract: Provided herein are methods of producing erythrocytes from hematopoietic cells, particularly hematopoietic cells from placental perfusate in combination with hematopoietic cells from umbilical cord blood, wherein the method results in accelerated expansion and differentiation of the hematopoietic cells to more efficiently produce administrable erythrocytes. Further provided herein is a bioreactor in which hematopoietic cell expansion and differentiation takes place.
    Type: Application
    Filed: October 28, 2015
    Publication date: August 24, 2017
    Applicant: Anthrogenesis Corporation
    Inventors: Mohammad A. Heidaran, Xiaokui Zhang, Lin Kang, Andrew Zeitlin, Vanessa Voskinarian-Berse, Stewart Abbot
  • Publication number: 20170002322
    Abstract: Provided herein are methods of producing natural killer cells using a two-step expansion and differentiation method. Also provided herein are methods of suppressing tumor cell proliferation, of treating individuals having cancer or a viral infection, comprising administering the NK cells produced by the method to an individual having the cancer or viral infection.
    Type: Application
    Filed: September 12, 2016
    Publication date: January 5, 2017
    Applicant: Anthrogenesis Corporation
    Inventors: Robert J. HARIRI, Mohammad A. HEIDARAN, Stephen JASKO, Lin KANG, Eric LAW, Ajai PAL, Bhavani STOUT, Vanessa VOSKINARIAN-BERSE, Andrew ZEITLIN, Xiaokui ZHANG
  • Publication number: 20160298084
    Abstract: The present invention relates to a combination of placental stem cells and stem or progenitor cells derived from a second source, wherein the combination shows improved engraftment as compared to placental stem cells or stem cells from a second source, alone. The combination is referred to as a combined stem cell population. The invention also provides in vitro and in vivo methods for identifying and producing combined stem cell populations, and models of engraftment. In accordance with the present invention, the placental stem cells may be combined with, e.g., umbilical cord blood-derived stem or progenitor cells, fetal or neonatal stem cells or progenitor cells, adult stem cells or progenitor cells, hematopoietic stem cells or progenitor cells, stem or progenitor cells derived from bone marrow, etc.
    Type: Application
    Filed: June 22, 2016
    Publication date: October 13, 2016
    Applicant: ANTHROGENESIS CORPORATION
    Inventors: Mohammad Heidaran, Jia-Lun Wang, Andrew Zeitlin, Colleen Suzanne Dulaney
  • Patent number: 9464274
    Abstract: Provided herein are methods of producing natural killer cells using a two-step expansion and differentiation method. Also provided herein are methods of suppressing tumor cell proliferation, of treating individuals having cancer or a viral infection, comprising administering the NK cells produced by the method to an individual having the cancer or viral infection.
    Type: Grant
    Filed: November 18, 2014
    Date of Patent: October 11, 2016
    Assignee: Anthrogenesis Corporation
    Inventors: Robert J. Hariri, Mohammad A. Heidaran, Stephen Jasko, Lin Kang, Eric Law, Ajai Pal, Bhavani Stout, Vanessa Voskinarian-Berse, Andrew Zeitlin, Xiaokui Zhang
  • Publication number: 20160287635
    Abstract: Provided herein are placental perfusate, placental perfusate cells, and placenta-derived intermediate natural killer cells, and combinations thereof. Also provided herein are compositions comprising the same, and methods of using placental perfusate, placental perfusate cells, and placenta-derived intermediate natural killer cells, and combinations thereof, to suppress the growth or proliferation of tumor cells, cancer cells, and the like, and to treat individuals having tumor cells.
    Type: Application
    Filed: November 16, 2015
    Publication date: October 6, 2016
    Applicant: ANTHROGENESIS CORPORATION
    Inventors: Robert J. Hariri, Mohammad A. Heidaran, Lin Kang, Neerav Dilip Padliya, Ajai Pal, Vanessa Voskinarian-Berse, Andrew Zeitlin, Xiaokui Zhang
  • Patent number: 9216200
    Abstract: Provided herein are placental perfusate, placental perfusate cells, and placenta-derived intermediate natural killer cells, and combinations thereof. Also provided herein are compositions comprising the same, and methods of using placental perfusate, placental perfusate cells, and placenta-derived intermediate natural killer cells, and combinations thereof, to suppress the growth or proliferation of tumor cells, cancer cells, and the like, and to treat individuals having tumor cells.
    Type: Grant
    Filed: August 13, 2012
    Date of Patent: December 22, 2015
    Assignee: Anthrogenesis Corporation
    Inventors: Robert J. Hariri, Mohammad A. Heidaran, Lin Kang, Neerav Dilip Padliya, Ajai Pal, Vanessa Voskinarian-Berse, Andrew Zeitlin, Xiaokui Zhang
  • Patent number: 9200253
    Abstract: Provided herein are methods of producing erythrocytes from hematopoietic cells, particularly hematopoietic cells from placental perfusate in combination with hematopoietic cells from umbilical cord blood, wherein the method results in accelerated expansion and differentiation of the hematopoietic cells to more efficiently produce administrable erythrocytes. Further provided herein is a bioreactor in which hematopoietic cell expansion and differentiation takes place.
    Type: Grant
    Filed: August 6, 2008
    Date of Patent: December 1, 2015
    Assignee: Anthrogenesis Corporation
    Inventors: Mohammad A. Heidaran, Xiaokui Zhang, Lin Kang, Andrew Zeitlin, Vanessa R. Voskinarian-Berse, Stewart Ernest Abbott
  • Publication number: 20150072425
    Abstract: Provided herein are methods of producing natural killer cells using a two-step expansion and differentiation method. Also provided herein are methods of suppressing tumor cell proliferation, of treating individuals having cancer or a viral infection, comprising administering the NK cells produced by the method to an individual having the cancer or viral infection.
    Type: Application
    Filed: November 18, 2014
    Publication date: March 12, 2015
    Applicant: ANTHROGENESIS CORPORATION
    Inventors: Robert J. HARIRI, Mohammad A. HEIDARAN, Stephen JASKO, Lin KANG, Eric LAW, Ajai PAL, Bhavani STOUT, Vanessa VOSKINARIAN-BERSE, Andrew ZEITLIN, Xiaokui ZHANG
  • Patent number: 8926964
    Abstract: Provided herein are methods of producing natural killer cells using a two-step expansion and differentiation method. Also provided herein are methods of suppressing tumor cell proliferation, of treating individuals having cancer or a viral infection, comprising administering the NK cells produced by the method to an individual having the cancer or viral infection.
    Type: Grant
    Filed: July 13, 2011
    Date of Patent: January 6, 2015
    Assignee: Anthrogenesis Corporation
    Inventors: Robert J. Hariri, Mohammad A. Heidaran, Stephen Jasko, Lin Kang, Eric Law, Ajai Pal, Bhavani Stout, Vanessa Voskinarian-Berse, Andrew Zeitlin, Xiaokui Zhang
  • Publication number: 20140341867
    Abstract: Provided herein are methods for the treatment of stroke comprising administering to a stroke victim placental stem cells, populations of cells comprising placental stem cells, and/or compositions comprising placental stem cells.
    Type: Application
    Filed: August 1, 2014
    Publication date: November 20, 2014
    Inventors: Andrew Zeitlin, Ajai Pal
  • Publication number: 20140093488
    Abstract: Provided herein are placental perfusate, placental perfusate cells, and placenta-derived intermediate natural killer cells, and combinations thereof. Also provided herein are compositions comprising the same, and methods of using placental perfusate, placental perfusate cells, and placenta-derived intermediate natural killer cells, and combinations thereof, to suppress the growth or proliferation of tumor cells, cancer cells, and the like, and to treat individuals having tumor cells.
    Type: Application
    Filed: August 13, 2012
    Publication date: April 3, 2014
    Applicant: ANTHROGENESIS CORPORATION
    Inventors: Robert J. Hariri, Mohammad A. Heidaran, Lin Kang, Neerav Dilip Padliya, Ajai Pal, Vanessa Voskinarian-Berse, Andrew Zeitlin, Xiaokui Zhang
  • Patent number: 8455250
    Abstract: The present invention relates to a combination of placental stem cells and stem or progenitor cells derived from a second source, wherein the combination shows improved engraftment as compared to placental stem cells or stem cells from a second source, alone. The combination is referred to as a combined stem cell population. The invention also provides in vitro and in vivo methods for identifying and producing combined stem cell populations, and models of engraftment. In accordance with the present invention, the placental stem cells may be combined with, e.g., umbilical cord blood-derived stem or progenitor cells, fetal or neonatal stem cells or progenitor cells, adult stem cells or progenitor cells, hematopoietic stem cells or progenitor cells, stem or progenitor cells derived from bone marrow, etc.
    Type: Grant
    Filed: December 28, 2006
    Date of Patent: June 4, 2013
    Assignee: Anthrogenesis Corporation
    Inventors: Mohammad Heidaran, Jia-Lun Wang, Qian Ye, Andrew Zeitlin, Colleen Suzanne Delaney
  • Patent number: 8263065
    Abstract: Provided herein are placental perfusate, placental perfusate cells, and placenta-derived intermediate natural killer cells, and combinations thereof. Also provided herein are compositions comprising the same, and methods of using placental perfusate, placental perfusate cells, and placenta-derived intermediate natural killer cells, and combinations thereof, to suppress the growth or proliferation of tumor cells, cancer cells, and the like, and to treat individuals having tumor cells.
    Type: Grant
    Filed: September 29, 2008
    Date of Patent: September 11, 2012
    Assignee: Anthrogenesis Corporation
    Inventors: Robert J. Hariri, Mohammad A. Heidaran, Lin Kang, Neerav Dilip Padliya, Ajai Pal, Vanessa Voskinarian-Berse, Andrew Zeitlin, Xiaokui Zhang
  • Publication number: 20120148553
    Abstract: Provided herein are methods of producing natural killer cells using a two-step expansion and differentiation method. Also provided herein are methods of suppressing tumor cell proliferation, of treating individuals having cancer or a viral infection, comprising administering the NK cells produced by the method to an individual having the cancer or viral infection.
    Type: Application
    Filed: July 13, 2011
    Publication date: June 14, 2012
    Inventors: Robert J. HARIRI, Mohammad A. Heidaran, Stephen Jasko, Lin Kang, Eric Law, Ajai Pal, Bhavani Stout, Vanessa Voskinarian-Berse, Andrew Zeitlin, Xiaokui Zhang
  • Publication number: 20110280849
    Abstract: Provided herein are methods of suppressing tumor cell proliferation, of treating individuals having cancer or a viral infection, comprising contacting the tumor cells, or administering to the individual, placental perfusate, placental perfusate cells, or natural killer cells, e.g., placenta-derived intermediate natural killer cells, with an immunomodulatory compound or thalidomide.
    Type: Application
    Filed: March 24, 2011
    Publication date: November 17, 2011
    Applicant: Anthrogenesis Corporation
    Inventors: Xiaokui ZHANG, Lin Kang, Mohammad A. Heidaran, Stephen Jasko, Andrew Zeitlin, Ajai Pal, Robert J. Hariri
  • Publication number: 20100143312
    Abstract: Provided herein are compositions and methods of treatment of individuals having a disease, disorder or condition of the lung, comprising administering a therapeutically-effective amount of placental cells, e.g., placental stem cells.
    Type: Application
    Filed: November 23, 2009
    Publication date: June 10, 2010
    Inventors: Robert J. HARIRI, Herbert Faleck, Andrew Zeitlin